

Leqvio (Inclisiran) Infusion Order

Fax to 801.931.2631 or Email to intake@purehealthcare.com

PATIENT INFORMATION			
Patient Name:		_ DOB:	Phone:
Patient Sex: Patient Weigh	ıt: kg Patient Heigl	nt: in Patien	t Email:
Patient Status: ☐ New Patient ☐	Continuing Therapy	Last Infusion Dat	e (if applicable):
DIAGNOSIS DETAILS			
□ Pure hypercholesterolemia, un □ Familial hypercholesterolemia □ Mixed hyperlipidemia (ICD-10: □ Hyperlipidemia, unspecified (I □ ASCHD w/o angina pectoris (I □ Other: □ Allergies:	(ICD-10: E78.01) E78.2) CD-10: E78.5) CD-10: I25.10)	ICD-10 code:	:
ORDER DETAILS FOR LEQV	IO (INCLISIRAN)		
Leqvio (Inclisiran):			
☐ Initial Dose: 284mg/1.5ml via s☐ Maintenance Dose: 284mg/1.5 Instruction: Administer subcutaneously in the contraction of th	5ml via subcutaneous (SC	Q) injection every	-
Infusion Reaction Protocol: □ Pure Infusion Reaction Protoco □ Other Reaction Protocol (Plea		der)	
ANCILLARY ORDERS			
Lab Orders:	Lab Frequency:		
Additional Orders:			
PROVIDER INFORMATION			
Practice Name:	Provider Name:		
Signature:		Date:	Time:
Contact Person:	Contact Ph:		Email:
NPI #: Office P	h:	Office	Fax:
PURE INFUSION SUITES PR	EFERRED LOCATION		
City:	State:		



PATIENT INFORMATION

Leqvio (Inclisiran) Infusion Order

Fax to 801.931.2631 or Email to intake@purehealthcare.com

Patient Name:	_ DOB:		
REQUIRED DOCUMENTATION FOR EXPEDITED ORDER PROCESSING & INSURANCE APPROVAL			
 □ Include completed order, signed by provider (page 1) □ Include patient demographic and insurance informati □ Include patient's medication list □ Supporting clinical notes (H&P) support primary diagr □ Heterozygous familial hypercholesterolemia (ILDL ≥ 190mg/dL (≥ 155mg/dL if <16 years of age) Please mark any of the following criteria the Hele □ Presence of tendon xanthoma(s) in the patient patient patient patient yield in 1st of the patient patient patient patient patient statin? □ Ascus cornealis before age 45 □ AscvD - Does the patient's LDL remain ≥ 100r intensity statin? □ Yes □ No □ Has the patient tried and failed PCSK9 inhibito □ Has the patient tried and failed a high intensity □ Indicate any conditions the patient has: □ Acute coronary syndrome □ History of myo 	nosis HeFH) - Does the patient have a untreated P □ Yes □ No PFH patient meets: ent or 1st/2nd degree relative degree relative or <50 years old in 2nd degree relative Omg/dL in a 1st/2nd degree relative omg/dL despite treatment with a high- r after 12 weeks of use? □ Yes □ No r statin for ≥ 8 continuous weeks? □ Yes □ No		
 □ Coronary or other arterial revascularization □ Peripheral arterial disease presumed to be □ Include labs and/or test results to support diagnosis □ LDL-C (required) □ Mutation in LDL, apoB, or PCSK9 gene (if approximately processed) 	of atherosclerotic origin		
□ Other medical necessity:			

Pure Healthcare will provide all necessary documents to the patient's insurance company to confirm eligibility. Our patient-obsessed will inform you if further details are needed. Additionally, we'll discuss financial obligations with the patient and direct them to co-pay assistance options as required.

Please submit BOTH pages & ALL supporting documentation. Fax to 801.931.2631 or Email to intake@purehealthcare.com